BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 8938284)

  • 1. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A; Huebler S; Merkle F; Hentschel T; GrĂ¼ndel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system.
    Rossi M; Storti S; Martinelli L; Varano C; Marra R; Zamparelli R; Possati G; Schiavello R
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):835-9. PubMed ID: 9412880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. Groningen Lung Transplant Group.
    Gu YJ; de Haan J; Brenken UP; de Boer WJ; Prop J; Van Oeveren W
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):599-606. PubMed ID: 8800145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
    Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
    Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
    Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
    Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery.
    Knudsen L; Hasenkam JM; Kure HH; Hughes P; Bellaiche L; Ahlburg P; Djurhuus C
    Thromb Res; 1996 Oct; 84(1):45-54. PubMed ID: 8885146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation.
    Grossmann R; Babin-Ebell J; Misoph M; Schwender S; Neukam K; Hickethier T; Elert O; Keller F
    Heart Vessels; 1996; 11(6):310-7. PubMed ID: 9248850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
    Baufreton C; Velthuis HT; Jansen PG; Besnerais PL; Wildevuur CH; Loisance DY
    ASAIO J; 1996; 42(5):M417-23. PubMed ID: 8944919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.
    Eisses MJ; Seidel K; Aldea GS; Chandler WL
    Anesth Analg; 2004 May; 98(5):1208-16, table of contents. PubMed ID: 15105189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
    Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
    Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.
    te Velthuis H; Baufreton C; Jansen PG; Thijs CM; Hack CE; Sturk A; Wildevuur CR; Loisance DY
    J Thorac Cardiovasc Surg; 1997 Jul; 114(1):117-22. PubMed ID: 9240301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.